嵌合抗原受体修饰T细胞治疗前列腺癌的研究进展  

Advances in the treatment of prostate cancer by chimeric antigen receptor modified T cells

作　　者：尤祥云 向振东 易成[2] 张满[2] 喻俊峰[2] YOU Xiang-yun;XIANG Zhen-dong;YI Cheng;ZHANG Man;YU Jun-feng(Department of Urology,the People’s Hospital of China Three Gorges University,Yichang 443000,China;Department of Urology,the First People’s Hospital of Yichang)

机构地区：[1]三峡大学人民医院泌尿外科,443000 [2]湖北省宜昌市第一人民医院泌尿外科

出　　处：《天津医药》2020年第10期1020-1024,共5页Tianjin Medical Journal

基　　金：宜昌市财政科技专项基金资助项目(A20-2-021)。

摘　　要：嵌合抗原受体修饰T细胞(CAR-T)是近年来免疫治疗的热点,在血液系统疾病的治疗中取得了显著的临床疗效。目前,CAR-T在前列腺癌(PCa)治疗的研究中也取得了较大进展,其中以前列腺特异性膜抗原(PSMA)和前列腺干细胞抗原(PSCA)为靶点的CAR-T治疗进展较快,其可显著抑制肿瘤细胞生长,一定程度地延缓疾病进展。本文综述了前列腺肿瘤相关抗原(TAA)在前列腺癌CAR-T治疗中的最新研究进展,并对CAR-T在前列腺癌治疗中的挑战予以简要探讨,以期为临床提供参考。The research of chimeric antigen receptor modification T cells(CAR-T)is a hotspot in immunotherapy in recent years,which has achieved remarkable clinical efficacy in the treatment of hematological diseases.At present,CAR-T has also made great progress in the treatment of prostate cancer(PCa).CAR-T therapy targeting prostate-specific membrane antigen(PSMA)and prostate-stem cell antigen(PSCA)has made rapid progresses,which can significantly inhibit tumor cell growth and delay disease progression in a certain extent.This article reviewed the recent clinical research progress of prostate cancer associated antigen(TAA)in the treatment of prostate cancer with CAR-T,and briefly discussed the challenges of CAR-T in the treatment of prostate cancer for better clinical application.

关 键 词：前列腺肿瘤 免疫治疗 嵌合抗原受体修饰T细胞 前列腺特异性膜抗原 前列腺干细胞抗原 

分 类 号：R737.25[医药卫生—肿瘤]